NDRA Insider Trading Activity and SEC Form 4 Filings
NDRA insider trading summary
No open-market insider purchases or sales of ENDRA Life Sciences Inc. (NDRA) have been reported on SEC Form 4 in the past 12 months.
Latest NDRA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 27, 2024 | UBS Group AG | 10% Owner | Buy | $2K (3,715 @ $0.55) |
| May 18, 2023 | Michael Milos Thornton | Chief Technology Officer | Buy | $25K (15,000 @ $1.65) |
| May 2, 2023 | Anthony Digiandomenico | Director | Buy | $100K (83,333 @ $1.20) |
| Dec 9, 2022 | Michael Milos Thornton | Chief Technology Officer | Buy | $5K (1,500 @ $3.40) |
| Nov 23, 2022 | Alexander Y Tokman | Director | Buy | $2K (10,000 @ $0.17) |
| Aug 22, 2022 | Alexander Y Tokman | Director | Buy | $5K (20,000 @ $0.26) |
| Aug 22, 2022 | Michael Milos Thornton | Chief Technology Officer | Buy | $5K (20,000 @ $0.27) |
| May 26, 2022 | Michael Milos Thornton | Chief Technology Officer | Buy | $5K (25,000 @ $0.21) |
| May 18, 2022 | Michael Milos Thornton | Chief Technology Officer | Buy | $6K (25,000 @ $0.22) |
| May 17, 2022 | Francois Roger Michelon | Chief Executive Officer | Buy | $969 (5,100 @ $0.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.